5-Amino-1MQ is a small-molecule NNMT inhibitor researched for its potential role in regulating energy balance, metabolic function, and adiposity. While the compound is also available in lyophilized powder form for
Tirz (GLP-2) 30mg
$185.00Tirzepatide is a long-acting synthetic polypeptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways, it has been
AOD-9604 5mg
$60.00⚠️ IMPORTANT RECONSTITUTION NOTICE ⚠️ AOD-9604 is a pH sensitive, hydrophobic peptide and typically requires Acetic Acid Solution before Bacteriostatic Water for successful reconstitution. Attempting to
Tirz (GLP-2) 10mg
$95.00Tirzepatide is a long-acting synthetic polypeptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways, it has been
5-Amino-1MQ 50mg
$116.005-Amino-1MQ is a small-molecule research compound investigated for its effects on cellular energy balance and fat metabolism. Unlike retail capsule formulations, this overview pertains to the lyophilized powder presentation intended
Semax 10mg
$60.00Semax is a synthetic polypeptide derived from the ACTH(4–7) fragment, designed to retain central nervous system–related properties without the classical corticotropic effects of native ACTH. Research efforts have examined its
DSIP 10mg
$65.00Delta Sleep-Inducing Peptide (DSIP) is a small, naturally occurring peptide made of nine amino acids. It was first discovered in the brain during early studies on deep, slow-wave sleep. Although
PT-141 10mg
$60.00PT-141, also known as Bremelanotide, is a synthetic peptide analog of the melanocortin receptor agonist Melanotan II. Unlike other agents studied for sexual function that primarily act via vascular mechanisms,
Tirz (GLP-2) 20mg
$150.00Tirzepatide is a long-acting synthetic polypeptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways, it has been
